Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Equity Offerings

Aclaris Therapeutics (ACRS) Prices 8.6645M Share Common Offering at $10.75/ShOctober 18, 2018 5:45 AM Aclaris Announces Proposed Public Offering of Common StockOctober 17, 2018 4:01 PM Aclaris Therapeutis (ACRS) PT Lowered to $34 at JMP SecuritiesOctober 16, 2018 3:18 AM After-Hours Stock Movers 10/15: (SEND) (ADBE) (ULBI) Higher; (JELD) (TWLO) (ACRS) Lower (more...)October 15, 2018 5:57 PM Aclaris Therapeutics (ACRS) to Resume Trading at 4:30 pm ETOctober 15, 2018 4:04 PM Aclaris Therapeutics (ACRS) to Acquire Rights to RHOFADE from Allergan (AGN) for Over $65MOctober 15, 2018 4:02 PM Aclaris Therapeutics (ACRS) Halted, News PendingOctober 15, 2018 4:00 PM